tradingkey.logo
tradingkey.logo
Search

Organogenesis falls after joint disease therapy fails to meet late-stage study goal

ReutersSep 25, 2025 10:23 PM
facebooktwitterlinkedin
View all comments0

Shares of Organogenesis ORGO.O fall 11.1% to $4.16 in extended trade

Company says its experimental therapy, ReNu, did not meet the main goal in its second late-stage trial for knee osteoarthritis, despite showing numerical improvement in pain reduction

Knee osteoarthritis is a degenerative joint condition where the protective cartilage in the knee wears away, leading to pain, stiffness, swelling and a grinding or crackling sensation with movement

As of last close, stock up 46.2% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI